[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-370342-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-370342-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","breast-tumors-from-atm-pathogenic-variant-carriers-display-a-specific-genome-wide-dna-methylation-profile","Breast tumors from ATM pathogenic variant carriers display a specific genome-wide DNA methylation profile","","ATM is a DNA damage response kinase whose heterozygous pathogenic variant (PV) carriers face increased cancer risk, especially breast cancer. This study evaluates whether genome-wide DNA methylation profiling can serve as a biomarker to detect tumors arising in ATM PV carriers and to support optimized therapy decisions. Using breast tumor-enriched DNA from ATM PV carriers, uncertain variant cases, A-T patients, and noncarriers, the work applies Illumina HumanMethylation EPIC/450K arrays and integrates methylation with gene expression and deep-learning models.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/breast-tumors-from-atm-pathogenic-variant-carriers-display-a-specific-genome-wide-dna-methylation-profile/370342/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/breast-tumors-from-atm-pathogenic-variant-carriers-display-a-specific-genome-wide-dna-methylation-profile/370342.png","ImageObject",300,407,{"name":42,"@type":43},"Levi","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-11","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What question does the study address about ATM PV carriers and breast cancer?","Question",{"text":63,"@type":64},"It investigates whether genome-wide DNA methylation profiling can identify tumors that arise in ATM pathogenic variant carriers, enabling biomarker-based support for clinical management and tailoring of therapies.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were DNA methylation profiles generated in this study?",{"text":68,"@type":64},"Breast tumor-enriched DNA was analyzed using Illumina HumanMethylation EPIC and 450K BeadChips. Promoter methylation was assessed for tumors with available transcriptomic data.",{"name":70,"@type":61,"acceptedAnswer":71},"What key methylation findings differentiate ATM PV carrier tumors from noncarrier tumors?",{"text":72,"@type":64},"The ATM promoter was hypermethylated in 62% of tumors from heterozygous PV carriers compared with noncarrier tumors. The study also highlights multiple hypermethylated gene promoters linked to lower gene expression and identifies additional predictive biomarkers using deep learning.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},370342,1790239937,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":109,"preview_page_count":33,"preview_urls":146},7971461740909,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Viart etal. Breast Cancer Research (2025) 27:36 Breast Cancer Research  \n[https://doi.org/10.1186/s13058-025-01988-w](https://doi.org/10.1186/s13058-025-01988-w)  \nRESEARCH Open Access  \nBreast tumors from ATM pathogenic variant  carriers display a specific genome-wide DNA methylation profile  \nNicolas M. Viart 1, Anne-Laure Renault 1,2, Séverine Eon-Marchais 1, Yue Jiao 1, Laetitia Fuhrmann3, Sophia Murat El Houdigui 1, Dorothée Le Gal 1, Eve Cavaciuti 1, Marie-Gabrielle Dondon 1, Juana Beauval let 1, Virginie Raynal4, Dominique Stoppa-Lyonnet5, Anne Vincent-Salomon3, Nadine Andrieu 1†, Melissa  \nC. Southey2,6† and Fabienne Lesueur 1*  \nAbstract  \nBackground The ataxia-telangiectasia mutated (ATM) kinase phosphorylates and activates several downstream targets that are essential for DNA damage repair, cell cycle inhibition and apoptosis. Germline biallelic inactivation of the ATM gene causes ataxia-telangiectasia (A-T), and heterozygous pathogenic variant (PV) carriers are at increased risk of cancer, notably breast cancer. This study aimed to investigate whether DNA methylation profiling can be useful as a biomarker to identify tumors arising in ATM PV carriers, which may help for the management and optimal tailoring of therapies of these patients.  \nMethods Breast tumor enriched DNA was prepared from 2 A-T patients, 27 patients carrying an ATM PV, 6 patients carrying a variant of uncertain clinical significance and 484 noncarriers enrolled in epidemiological studies conducted in France and Australia to investigate genetic and nongenetic factors involved in breast cancer susceptibility.  \nGenome-wide DNA methylation analysis was performed using the Il lumina Infinium HumanMethylation EPIC and 450K BeadChips. Correlation between promoter methylation and gene expression was assessed for 10 tumors for which transcriptomic data were available.  \nResults We found that the ATM promoter was hypermethylated in 62% of tumors of heterozygous PV carriers compared to the mean methylation level of ATM promoter in tumors of noncarriers. Gene set enrichment analyses identified 47 biological pathways enriched in hypermethylated genes involved in neoplastic, neurodegenerative and metabolic-related pathways in tumor of PV carriers. Among the 327 differential ly methylated promoters, promoters of ARHGAP40, SCGB3A1 (HIN-1), and CYBRD1 (DCYTB) were hypermethylated and associated with a lower gene expression in these tumors. Moreover, using three different deep learning algorithms (logistic regression, random forest and  \n†Nadine Andrieu and Melissa C. Southey contributed equally to this work.  \n*Correspondence: Fabienne Lesueur [fabienne.lesueur@curie.fr](fabienne.lesueur@curie.fr)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/l](vecommons.org/l)icenses/by-nc-nd/4.0/.  \nViart et al. Breast Cancer Research (2025) 27:36 Page 2 of 16  \nXGBoost), we identified a set of 27 additional biomarkers predictiv","cbCaiubWsEbYYA79","https://ap.wps.com/l/cbCaiubWsEbYYA79","pdf",5328971,16,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Keywords\n# Background","[{\"question\":\"What question does the study address about ATM PV carriers and breast cancer?\",\"answer\":\"It investigates whether genome-wide DNA methylation profiling can identify tumors that arise in ATM pathogenic variant carriers, enabling biomarker-based support for clinical management and tailoring of therapies.\"},{\"question\":\"How were DNA methylation profiles generated in this study?\",\"answer\":\"Breast tumor-enriched DNA was analyzed using Illumina HumanMethylation EPIC and 450K BeadChips. Promoter methylation was assessed for tumors with available transcriptomic data.\"},{\"question\":\"What key methylation findings differentiate ATM PV carrier tumors from noncarrier tumors?\",\"answer\":\"The ATM promoter was hypermethylated in 62% of tumors from heterozygous PV carriers compared with noncarrier tumors. The study also highlights multiple hypermethylated gene promoters linked to lower gene expression and identifies additional predictive biomarkers using deep learning.\"}]","Breast tumors from ATM pathogenic variant carriers display a specific genome-wide DNA methylation profile | PDF",1790188130,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/efa4ebdf344a6e16d6cf73c87b2774a8.webp",983,1310,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a8b9ac08613fc385764274ba323ec98b.webp",982,1309,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/18ca34a449568aae05e3ad205d6ef887.webp",981,1308,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/83408c49ea481070e6b2c81e3db9aacc.webp",980,1306]